Android app Apple app link

Bristol Myers's stock soars after AbbVie's schizophrenia-drug trial disappoints

By MarketWatch   |   1 year ago
Bristol Myers's stock soars after AbbVie's schizophrenia-drug trial disappoints

Bristol Myers Squibb's stock rose by 12.5% following AbbVie's announcement of disappointing trial results for their new schizophrenia drug, causing AbbVie's shares to drop by 12.4%.

Read More

Did you find this insightful?

Exclusive Content

Access to this content is reserved for premium members. Unlock all features by upgrading to a premium membership.

Get the App

To join as a premium member, please download our app and complete your membership purchase there.